Review does not support monthly lab testing for oral isotretinoin use for acne

December 02, 2015

A review of medical literature does not support monthly laboratory testing for all patients who are using standard doses of the acne medication isotretinoin, according to an article published online by JAMA Dermatology.

Isotretinoin has been associated with several adverse effects, including teratogenicity (causing birth defects) and hyperlipidemia. Prior studies have looked at the usefulness of laboratory monitoring during isotretinoin therapy.

Joslyn S. Kirby, M.D., M.Ed., M.S., of the Penn State Milton S. Hershey Medical Center, Hershey, Penn., and coauthors reviewed medical literature to estimate changes in laboratory tests during isotretinoin therapy.

The authors included 26 studies (1,574 patients) in their meta-analysis, which evaluated laboratory test results for lipid levels, hepatic (liver) function and complete blood cell counts.

Results suggest that while isotretinoin was associated with a change in the average value of some laboratory tests (white blood cell count and hepatic and lipid panels), the average change across a patient group did not meet the criteria for high-risk and the proportion of patients with laboratory abnormalities was low, the authors report.

However, the authors note their study should be considered in the context of some limitations, which include that the analysis was limited by the availability of data and the completeness of reports. Authors also did not have access to information about patients or the treatment so specific laboratory changes could not be correlated with doses or dose changes.

"The findings of this study suggest that less frequent laboratory monitoring may be safe, with few missed high-risk laboratory changes, for many patents with acne who are receiving typical doses of isotretinoin. ... A decrease in the frequency of laboratory monitoring for some patients could help to decrease health care spending and potential anxiety-provoking blood sampling," the study concludes.

(JAMA Dermatology. Published online December 2, 2015. doi:10.1001/jamadermatol.2015.3091. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor's Note: This study was supported by a grant from the American Acne and Rosacea Society. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Editorial: A Call to Decrease Testing in an Era of High-Value, Cost-Conscious Care

"More than 7,000 personal injury lawsuits associated with isotretinoin have been filed, and hundreds are still pending. Although many of these associations have not been well substantiated by scientific evidence, the heightened perception of possible drug-related adverse effects is suggested by the unusually high number of legal proceedings related to this particular drug. In the face of these controversies, changing our practice of laboratory test monitoring relies not only on evidence provided by key studies such as this one but may additionally require discussion within the dermatology community and possibly even endorsement or guidelines issued from key opinion leaders to gain wide acceptance," write Eleni Linos, M.D., M.P.H., Dr.PH., of the University of California, San Francisco, and coauthors in a related editorial.

(JAMA Dermatology. Published online December 2, 2015. doi:10.1001/jamadermatol.2015.3128. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor's Note: Authors made conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
-end-
Media Advisory: To contact corresponding author Joslyn S. Kirby, M.D., M.Ed., M.S., call Matthew G. Solovey at 717-531-0003, x287127 or email msolovey@hmc.psu.edu. To contact corresponding editorial author Eleni Linos, M.D., M.P.H., call Elizabeth Fernandez at 415-514-1592 or email Elizabeth.Fernandez@UCSF.edu.

The JAMA Network Journals

Related Acne Articles from Brightsurf:

Trifarotene in moderate acne: No study data for the assessment of the added benefit
Trifarotene in moderate acne: no study data for the assessment of the added benefit.

It cures acne, afib, anxiety? CBD users think its real medicine, contrary to evidence
A new study published in JAMA Network Open finds that as many as 90 percent of CBD users think it's real medicine, taking CBD to treat nearly all medical conditions, including substance use withdrawal, atrial fibrillation, and erectile dysfunction, to name a few.

Fighting cardiovascular disease with acne drug
Researchers from the European Molecular Biology Laboratory (EMBL) in Heidelberg and Stanford University have found the cause of dilated cardiomyopathy - a leading cause of heart failure - and identified a potential treatment for it: a drug already used to treat acne.

Anatomy of an acne treatment
Sarecycline, a drug approved for use in the United States in 2018, is the first new antibiotic approved to treat acne in more than 40 years.

Probiotics may help treat acne
Acne is caused by chronic inflammation and is often treated with antibiotics.

Doctors urged to reconsider controversial acne drug
Acne treatment including the highly effective acne medication isotretinoin should be made more readily available despite reports of its association with depression and teen suicide, a study recommends.

Are there racial/ethnic disparities in treatment for acne?
Whether there are differences in treatment of acne by race/ethnicity, sex and type of insurance was the focus of this observational study that analyzed treatment and prescribing patterns for acne for nearly 30,000 patients.

Does blue light therapy help acne? Efficacy and evidence is lacking
Conclusions about the effectiveness of blue light therapy for acne are limited.

Daily consumption of sweets, cakes and unhealthy foods associated with acne, study reveals
The research, presented at the 28th EADV Congress in Madrid, evaluated the exposure to different worsening factors on acne more than 6,700 participants across six countries in North America, South America and Europe.

Teenage acne may be a natural, transient inflammatory state
Adolescent acne does not always result in a pathological condition; rather, it may be a natural, transient inflammatory state occurring when the maturing facial skin is exposed to new microbes and enhanced production of an oily substance called sebum.

Read More: Acne News and Acne Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.